| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2009 | WO2009016560A2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| 02/05/2009 | WO2009016536A2 Preservative compositions for moist wipes |
| 02/05/2009 | WO2009016498A1 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions |
| 02/05/2009 | WO2009016462A2 Substituted bicyclolactam compounds |
| 02/05/2009 | WO2009016460A2 Pyrazole compounds and their use as raf inhibitors |
| 02/05/2009 | WO2009016440A1 Effervescent solid pharmaceutical composition comprising dextrose and process for its preparation |
| 02/05/2009 | WO2009016425A1 Compounds of chemical synthesis with antirhinovirus activity |
| 02/05/2009 | WO2009016414A1 Novel process |
| 02/05/2009 | WO2009016390A1 Anti-inflammatory composition |
| 02/05/2009 | WO2009016379A2 Nr4a agonists ( 6-mercaptopurine) for inhibition of non-ocular scarring |
| 02/05/2009 | WO2009016359A1 New forms of deferasirox |
| 02/05/2009 | WO2009016358A2 Pharmaceutical compositions and process for making them |
| 02/05/2009 | WO2009016350A2 Stimulating gel |
| 02/05/2009 | WO2009016333A1 Osteogenic compounds |
| 02/05/2009 | WO2009016329A1 Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions |
| 02/05/2009 | WO2009016286A2 6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof |
| 02/05/2009 | WO2009016269A1 Water-soluble ethylidene phosphate prodrug of propofol |
| 02/05/2009 | WO2009016253A2 Cyanomethyl substituted n-acyl tryptamines |
| 02/05/2009 | WO2009016241A1 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators |
| 02/05/2009 | WO2009016227A2 Novel compounds |
| 02/05/2009 | WO2009016225A1 1-piperidinyl-6-piperidinylsulfonylindoles as 5-ht (2b) receptor antagonists |
| 02/05/2009 | WO2009016218A2 Fungicide n-cycloalkyl-n-bicyclic-carboxamide derivatives |
| 02/05/2009 | WO2009016216A1 Triazole derivatives as scd inhibitors |
| 02/05/2009 | WO2009016191A1 Process for preparing a leukotriene antagonist and an intermediate thereof |
| 02/05/2009 | WO2009016142A1 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a derivatives and their use for the treatment of malaria |
| 02/05/2009 | WO2009016132A1 Pyrrolopyrimidines |
| 02/05/2009 | WO2009016119A1 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus |
| 02/05/2009 | WO2009016118A1 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus |
| 02/05/2009 | WO2009016088A1 The use of benzamide derivatives for the treatment of cns disorders |
| 02/05/2009 | WO2009016087A1 Monoamide derivatives as orexin receptor antagonists |
| 02/05/2009 | WO2009016085A1 Spiro compounds useful as antagonists of the h1 receptor |
| 02/05/2009 | WO2009016084A1 Spiro cyclopentane compounds useful as antagonists of the h1-receptor |
| 02/05/2009 | WO2009016072A2 A morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| 02/05/2009 | WO2009016048A1 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| 02/05/2009 | WO2009015996A2 Reduction of oxidative stress damage during or after exercise |
| 02/05/2009 | WO2009015981A2 Treatment of pediatric tumors |
| 02/05/2009 | WO2009015897A1 Novel heterocyclic compounds as mglu5 antagonists |
| 02/05/2009 | WO2009015892A1 Adefovir dipivoxil crystalline monohydrate form |
| 02/05/2009 | WO2009015891A1 Use of phosphatidylcholine for treating steroid-dependent and steroid-refractory ulcerative colitis |
| 02/05/2009 | WO2009015879A1 Cachexia prevention supplement |
| 02/05/2009 | WO2009015867A1 Substituted aryl or heteroarylpiperdine derivatives as melanocortin-4 receptor modulators |
| 02/05/2009 | WO2009015844A1 Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| 02/05/2009 | WO2009015828A1 Paliperidone derivatives |
| 02/05/2009 | WO2009015812A2 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile |
| 02/05/2009 | WO2009015811A1 Dipeptoid prodrugs and the use thereof |
| 02/05/2009 | WO2009015776A1 Substituted aryloxazoles and the use thereof |
| 02/05/2009 | WO2009015766A1 Single-phase pharmaceutical composite preparation (dienogest and ethinyl estradiol) for oral therapy for regulation of blood pressure |
| 02/05/2009 | WO2009015734A2 Dosage form comprising immediate release naproxen and sustained release opioid analgesic |
| 02/05/2009 | WO2009015667A1 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
| 02/05/2009 | WO2009015561A1 The use of leonurine and compositions thereof |
| 02/05/2009 | WO2009015560A1 Use of allylcysteine or its analogs and pharmaceutical composition threrof |
| 02/05/2009 | WO2009015543A1 Cyclohexenone compounds from antrodia camphorata and pharmaceutical compositions thereof useful for treating autoimmune diseases |
| 02/05/2009 | WO2009015541A1 Polyene diester antibiotics |
| 02/05/2009 | WO2009015491A1 Umps isoforms as novel predictive markers and therapeutic targets for chemotherapeutics |
| 02/05/2009 | WO2009015485A1 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| 02/05/2009 | WO2009015447A2 Polyacetal-carboxylic acids in the treatment of cancer and auto-immune disorders |
| 02/05/2009 | WO2009015446A2 Triazole derivatives as viral replication inhibitors |
| 02/05/2009 | WO2009000168A1 An antrodia camphorata cyclohexenone compound used for decreasing physiological fatigue |
| 02/05/2009 | WO2008157614A3 Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
| 02/05/2009 | WO2008154590A3 Predicting responsiveness to temozolomide |
| 02/05/2009 | WO2008153958A3 Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| 02/05/2009 | WO2008153394A3 Novel anti-inflammatory pro-drugs |
| 02/05/2009 | WO2008153391A3 Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| 02/05/2009 | WO2008150830A3 Metal complexes incorporated within biodegradable nanoparticles and their use |
| 02/05/2009 | WO2008150486A3 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| 02/05/2009 | WO2008150245A3 Stable formulation of amorphous perindopril salts, a process for the preparation thereof on industrial scale and use thereof in the treatment of hypertension |
| 02/05/2009 | WO2008149192A3 Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
| 02/05/2009 | WO2008144223A3 Triazolyl aminopyrimidine compounds |
| 02/05/2009 | WO2008139124A3 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
| 02/05/2009 | WO2008139122A3 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
| 02/05/2009 | WO2008137787A3 Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| 02/05/2009 | WO2008137236A3 Treatment of age-related macular degeneration using inhibitors of complement factor d |
| 02/05/2009 | WO2008137207A3 Inactivators of o6-alkylguanine-dna alkyltransferase |
| 02/05/2009 | WO2008137134A3 Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide |
| 02/05/2009 | WO2008136863A3 Synthesis of compounds useful as modulators of amyloid-beta production |
| 02/05/2009 | WO2008135826A3 2 -pyridine carboxamide derivatives as sodium channel modulators |
| 02/05/2009 | WO2008134557A3 Solid dosage forms |
| 02/05/2009 | WO2008132682A3 Improved vitamin d content uniformity in pharmaceutical dosage forms |
| 02/05/2009 | WO2008129054A3 Heterocyclic compounds with affinity to muscarinic receptors |
| 02/05/2009 | WO2008128919A3 Histamine h3 receptor ligands comprising a cyclobutoxy group |
| 02/05/2009 | WO2008124703A3 Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry |
| 02/05/2009 | WO2008122534A3 Non-nucleoside reverse transcriptase inhibitors |
| 02/05/2009 | WO2008121813A3 Modulation of cytokine production |
| 02/05/2009 | WO2008118122A8 Compounds and amyloid probes thereof for therapeutic and imaging uses |
| 02/05/2009 | WO2008116912A3 Purinyl derivatives and their use as potassium channel modulators |
| 02/05/2009 | WO2008114114A3 Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| 02/05/2009 | WO2008111919A3 A novel combination of water-soluble forms of coenzyme q10 and l-carnitine, process of production and use |
| 02/05/2009 | WO2008109558A3 Nucleic acid compounds for inhibiting tlr gene expression and uses thereof |
| 02/05/2009 | WO2008109531A3 Nucleic acid compounds for inhibiting hsd11b1 expression and uses thereof |
| 02/05/2009 | WO2008109120A3 P53-mediated skin pigmentation |
| 02/05/2009 | WO2008108957A3 Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain |
| 02/05/2009 | WO2008104203A3 18f fluoro-benzoyl labelled biological active coumpounds as diagnositic imaging agents as well as benzotriazol-1-yloxy-benzoyl, 2,5-dioxo-pyrrolidin-1-yloxy) benzoyl and trimethylammonio-benzoyl precursers |
| 02/05/2009 | WO2008065637A9 Treatment of disease |
| 02/05/2009 | WO2008047951A3 An alzheimer' s disease progression inhibitor containing heterocyclic compound |
| 02/05/2009 | WO2008045017A3 Sars and ebola inhibitors and use thereof, and methods for their discovery |
| 02/05/2009 | WO2008028032A4 Therapeutic substituted hydantoins and related compounds |
| 02/05/2009 | WO2008016640A3 Use of poloxamer for the prevention and/or treatment of heart failure |
| 02/05/2009 | WO2007127867A3 Chromium complexes |
| 02/05/2009 | WO2007101710A8 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases |
| 02/05/2009 | WO2007003521A3 Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors |